Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and...
Read More
Oncology
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant)....
Read MoreDatopotamab deruxtecan may be a novel improvement for inoperable breast cancer
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) datopotamab deruxtecan...
Read More
Ponsegromab for the Treatment of Cancer Cachexia
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo;...
Read More
Naldemedine may be effective for opioid-induced constipation in patients with cancer
1. In a randomized double-blind placebo-controlled study, naldemedine use was associated with...
Read More
False-positive mammography results may deter women from continued screening
1. In this cohort study, women were less likely to return for mammogram screening if their...
Read More
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar...
Read More
Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients
1. In a retrospective analysis of 59,875 patients with metastatic prostate cancer, varying...
Read More
Patient Education Needed to Successfully Integrate PROs Into EHRs
Patients found high value in integrating patient-reported outcomes into electronic health records, but expressed several areas of confusion.
Read More
EHR Nudge Can Reduce Unnecessary Sentinel Lymph Node Biopsy
An EHR nudge intervention targeting surgeons can reduce sentinel lymph node biopsy (SLNB) among women who meet the Choosing Wisely criteria for SLNB omission.
Read More
Esophageal Cancer Disparities Declined From 1999 to 2020
From 1999 to 2020, age-adjusted esophageal cancer mortality decreased among Black adults but stabilized among White adults.
Read More
Substantial Disparities Seen for Men in Cancer Cases & Deaths
Disparities seen in cancer incidence and mortality among men across age groups and countries/territories for 2022 are projected to widen further by 2050.
Read More
Rare Cancers Associated With Poor Psychological Outcomes
Researchers found an increased risk ratio for depression and anxiety among patients with rare cancers, as well as higher incidences of suicide and PTSD.
Read More
Medication-related osteonecrosis of the jaw is prevalent in patients with breast cancer
1. The cumulative incidence of medication-related osteonecrosis of the jaw (MRONJ) in patients...
Read More
Machine learning algorithm demonstrates ability to appropriately identify cancer patients for serious illness conversations
1. Patel and colleagues conducted a secondary economic analysis of a trial that assigned high-risk...
Read More
Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2....
Read More
Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma
1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs...
Read More
Alternative lung cancer screening criteria may increase sensitivity versus current guidelines
1. In this modeling study, an alternative set of lung cancer screening criteria was more sensitive...
Read More
Cancer screening costs in the United States may exceed $40 billion annually
1. In the United States, the estimated annual cost of cancer screening was $43 billion, with...
Read More
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy
1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus...
Read More